The Broad Institute of MIT and Harvard recently announced a new $15 million commitment by Louis V. Gerstner, Jr, former Corporate Executive Officer and Chairman of the Board of IBM Corporation, and Current Chairman of the Board of Directors of the Broad Institute, to create the Gerstner Center for Cancer Diagnostics at the Broad Institute. The new Center will be endowed with an additional commitment of $10 million by the Eli & Edythe Broad Foundation.
The Gerstner Center aims to advance blood-based biopsies for tracking disease progression and pursue other cancer diagnostics. The new center builds upon a major effort at the Broad Institute that focused on elucidating the mechanisms of cancer drug resistance. This work has already given rise to a project with IBM Watson Health to understand and prevent cancer progression. ■
